Acasti Pharma Price to Free Cash Flow Ratio 2014-2024 | GRCE
Historical price to free cash flow ratio values for Acasti Pharma (GRCE) since 2014.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Acasti Pharma Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-10-28 |
3.21 |
|
0.00 |
| 2024-06-30 |
2.92 |
$-0.77 |
0.00 |
| 2024-03-31 |
3.43 |
$-1.28 |
0.00 |
| 2023-12-31 |
2.89 |
$-1.33 |
0.00 |
| 2023-09-30 |
2.78 |
$-2.04 |
0.00 |
| 2023-06-30 |
3.15 |
$-2.25 |
0.00 |
| 2023-03-31 |
2.76 |
$-2.14 |
0.00 |
| 2022-12-31 |
3.01 |
$-2.59 |
0.00 |
| 2022-09-30 |
3.50 |
$-2.26 |
0.00 |
| 2022-06-30 |
5.15 |
$-2.76 |
0.00 |
| 2022-03-31 |
7.32 |
$-2.81 |
0.00 |
| 2021-12-31 |
7.56 |
$-1.69 |
0.00 |
| 2021-09-30 |
12.00 |
$-3.31 |
0.00 |
| 2021-06-30 |
26.95 |
$-4.38 |
0.00 |
| 2021-03-31 |
28.80 |
$-5.82 |
0.00 |
| 2020-12-31 |
15.60 |
$-8.00 |
0.00 |
| 2020-09-30 |
9.61 |
$-9.95 |
0.00 |
| 2020-06-30 |
22.52 |
$-11.25 |
0.00 |
| 2020-03-31 |
18.22 |
$-13.20 |
0.00 |
| 2019-12-31 |
117.60 |
$-21.91 |
0.00 |
| 2019-09-30 |
90.72 |
$-17.13 |
0.00 |
| 2019-06-30 |
54.72 |
$-19.65 |
0.00 |
| 2019-03-31 |
48.96 |
$-22.38 |
0.00 |
| 2018-12-31 |
39.93 |
$-18.88 |
0.00 |
| 2018-09-30 |
61.92 |
$-30.41 |
0.00 |
| 2018-06-30 |
27.36 |
$-30.46 |
0.00 |
| 2018-03-31 |
48.96 |
$-27.78 |
0.00 |
| 2017-12-31 |
45.25 |
$-28.04 |
0.00 |
| 2017-09-30 |
68.16 |
$-25.75 |
0.00 |
| 2017-06-30 |
63.36 |
$-24.89 |
0.00 |
| 2017-02-28 |
60.00 |
$-29.57 |
0.00 |
| 2016-11-30 |
67.20 |
$-45.77 |
0.00 |
| 2016-08-31 |
63.84 |
$-20.24 |
0.00 |
| 2016-05-31 |
72.00 |
$-31.34 |
0.00 |
| 2016-03-31 |
72.96 |
$-19.70 |
0.00 |
| 2016-02-29 |
72.00 |
0 |
0.00 |
| 2015-12-31 |
122.40 |
$-25.61 |
0.00 |
| 2015-09-30 |
129.07 |
$-18.04 |
0.00 |
| 2015-06-30 |
151.20 |
$-28.65 |
0.00 |
| 2015-03-31 |
230.16 |
$-26.74 |
0.00 |
| 2014-12-31 |
240.00 |
$-19.72 |
0.00 |
| 2014-09-30 |
369.60 |
$-17.19 |
0.00 |
| 2014-06-30 |
489.60 |
$3.14 |
155.85 |
| 2013-09-30 |
1137.60 |
$-24.12 |
0.00 |
| 2013-06-30 |
1358.40 |
$-11.42 |
0.00 |
| 2013-03-31 |
1022.40 |
$-16.82 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
